Immunological strategies to target HIV persistence
- PMID: 27054281
- DOI: 10.1097/COH.0000000000000289
Immunological strategies to target HIV persistence
Abstract
Purpose of review: The purpose of this article is to review recent advances in immunotherapeutic approaches aiming at reducing the latent HIV reservoir.
Recent findings: HIV-1 establishes early during infection a pool of latently infected cells that persist long term and are largely undetectable to the immune system. Highly active antiretroviral therapy has dramatically improved the life expectancy and life quality of HIV-1-infected individuals, but is incapable of eliminating the pool of latently HIV-1-infected cells. Recent studies have started to test immunotherapeutic interventions in combination with latency reversing agents to reduce the latent HIV-1 reservoir, including approaches aimed at enhancing antiviral T-cell immunity, innate immunity, and virus-specific antibodies.
Summary: The better understanding of virus-specific immunity and the pathways used by HIV-1 to evade host immune responses have enabled the development of new strategies focusing on targeting latently HIV-1-infected cells, with the goal to reduce the HIV-1 reservoir. Here, we will review recent advances in harnessing effector cells of the immune system, including CD8 T cells and natural killer cells, antiviral antibodies and new immunomodulatory molecules, to target HIV-1 persistence.
Similar articles
-
Kill: boosting HIV-specific immune responses.Curr Opin HIV AIDS. 2016 Jul;11(4):409-16. doi: 10.1097/COH.0000000000000286. Curr Opin HIV AIDS. 2016. PMID: 27054280 Free PMC article. Review.
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.J Clin Invest. 2015 Nov 2;125(11):4077-90. doi: 10.1172/JCI82314. Epub 2015 Sep 28. J Clin Invest. 2015. PMID: 26413868 Free PMC article.
-
Clinical Interventions in HIV Cure Research.Adv Exp Med Biol. 2018;1075:285-318. doi: 10.1007/978-981-13-0484-2_12. Adv Exp Med Biol. 2018. PMID: 30030798 Review.
-
Current views on HIV-1 latency, persistence, and cure.Folia Microbiol (Praha). 2017 Jan;62(1):73-87. doi: 10.1007/s12223-016-0474-7. Epub 2016 Oct 5. Folia Microbiol (Praha). 2017. PMID: 27709447 Review.
Cited by
-
Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.Clin Epigenetics. 2018 Feb 5;10:14. doi: 10.1186/s13148-018-0441-z. eCollection 2018. Clin Epigenetics. 2018. PMID: 29441145 Free PMC article. Review.
-
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.JCI Insight. 2017 Aug 17;2(16):e92901. doi: 10.1172/jci.insight.92901. eCollection 2017 Aug 17. JCI Insight. 2017. PMID: 28814661 Free PMC article.
-
Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.Front Pharmacol. 2024 Sep 23;15:1426974. doi: 10.3389/fphar.2024.1426974. eCollection 2024. Front Pharmacol. 2024. PMID: 39380908 Free PMC article.
-
Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal.Cell Chem Biol. 2018 Dec 20;25(12):1443-1455.e14. doi: 10.1016/j.chembiol.2018.08.004. Epub 2018 Sep 6. Cell Chem Biol. 2018. PMID: 30197195 Free PMC article.
-
Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity.J Immunol. 2018 Mar 1;200(5):1853-1864. doi: 10.4049/jimmunol.1701523. Epub 2018 Jan 26. J Immunol. 2018. PMID: 29374075 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
